Meanwhile, in an osteosarcoma model, TLR9 agonists remodel the immunosuppressive TME by reducing M2-like macrophages and increasing the infiltration of activated CD8+ T cells (101), indicating that TLR signaling can alter cytokine profiles in the TME, thereby influencing APCs, particularly macrophages, and modifying the course of tumor immunity. This evidence concerns the gene TLR9 and neoplasm.